{
    "symbol": "CRIS",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-09 19:36:04",
    "content": " For the third quarter of 2022, Curis reported a net loss of $13.3 million or $0.14 per share as compared to a net loss of $11.1 million or $0.12 per share for the same period in 2021. Curis reported a net loss of $45.3 million or $0.49 per share for the nine months ended September 30, 2022, as compared to a net loss of $31.8 million or $0.35 per share for the same period in 2021. Revenues for the nine months ended September 30, 2022 and September 30, 2021, were $7.3 million and $7.5 million, respectively. Operating expenses for the nine months ended September 30, 2022, were $50.1 million as compared to $37 million for the same period in 2021 and consists of the following: Cost of royalty revenues, which is comprised of amounts due to third-party university patent licensors in connection with Genentech and Roche\u00e2\u0080\u0099s Erivedge net sales were $0.1 million for the third quarter of 2022 as compared to $0.2 million for the same period in 2021. Cost of royalty revenues for the nine months ended September 30, 2022, were $0.2 million as compared to $0.4 million for the same period in 2021. Research and development expenses were $34.6 million for the nine months ended September 30, 2022, as compared to $24.1 million for the same period in 2021. General and administrative expenses were $4.6 million for the third quarter ended September 30, 2022, as compared to $4.3 million for the same period in 2021. General and administrative expenses were $15.3 million for the nine months ended September 30, 2022, as compared to $12.5 million for the same period in 2021. Other expense was $2.5 million for the nine months ended September 30, 2022, as compared to $2.3 million for the same period in 2021."
}